These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38383563)

  • 41. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer.
    Oweida AJ; Darragh L; Phan A; Binder D; Bhatia S; Mueller A; Court BV; Milner D; Raben D; Woessner R; Heasley L; Nemenoff R; Clambey E; Karam SD
    J Natl Cancer Inst; 2019 Dec; 111(12):1339-1349. PubMed ID: 30863843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
    Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
    Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
    Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
    [No Abstract]   [Full Text] [Related]  

  • 44. Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database.
    Almutairi AR; Slack M; Erstad BL; McBride A; Abraham I
    Ther Adv Drug Saf; 2021; 12():2042098621991279. PubMed ID: 33796257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
    Zhu P; Wang Y; Zhang W; Liu X
    Medicine (Baltimore); 2021 Jan; 100(4):e24339. PubMed ID: 33530227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mannosylated-serum albumin nanoparticle imaging to monitor tumor-associated macrophages under anti-PD1 treatment.
    Gu GJ; Chung H; Park JY; Yoo R; Im HJ; Choi H; Lee YS; Seok SH
    J Nanobiotechnology; 2023 Jan; 21(1):31. PubMed ID: 36707872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic impact of intra- and peritumoral immune cell subpopulations in head and neck squamous cell carcinomas - comprehensive analysis of the TCGA-HNSC cohort and immunohistochemical validation on 101 patients.
    Knebel M; Körner S; Kühn JP; Wemmert S; Brust L; Smola S; Wagner M; Bohle RM; Morris LGT; Pandey A; Schick B; Linxweiler M
    Front Immunol; 2023; 14():1172768. PubMed ID: 37383237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
    Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
    Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.
    Secrier M; McGrath L; Ng F; Gulati S; Raymond A; Nuttall BRB; Berthe J; Jones EV; Sidders BS; Galon J; Barrett JC; Angell HK
    Cancer Res Commun; 2023 Oct; 3(10):2133-2145. PubMed ID: 37819239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
    Chen S; Huang M; Zhang L; Huang Q; Wang Y; Liang Y
    Comput Struct Biotechnol J; 2024 Dec; 23():369-383. PubMed ID: 38226313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
    Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
    Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
    Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
    Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.
    Kundu K; Ghosh S; Sarkar R; Edri A; Brusilovsky M; Gershoni-Yahalom O; Yossef R; Shemesh A; Soria JC; Lazar V; Joshua BZ; Campbell KS; Elkabets M; Porgador A
    Cancer Immunol Res; 2019 Jul; 7(7):1120-1134. PubMed ID: 31164357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
    Le Meitour Y; Foy JP; Guinand M; Michon L; Karabajakian A; Fayette J; Saintigny P; Mahtouk K
    Oral Oncol; 2024 Feb; 149():106680. PubMed ID: 38218022
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetic control of
    Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
    Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.